Kyver­na says CAR-T man­u­fac­tur­ing times can be cut through blood col­lec­tion ef­fi­cien­cies 

Clin­i­cal-stage biotech Kyver­na Ther­a­peu­tics re­vealed fur­ther de­tails on how it can po­ten­tial­ly short­en pro­duc­tion time­lines for au­toim­mune CAR-Ts by us­ing its so-called “vein-to-vein” process. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER